Eradication of multidrug-resistant Acinetobacter baumannii in a female patient with total hip arthroplasty, with debridement and retention: a case report by Beieler, Alison M et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Journal of Medical Case Reports
Open Access Case report
Eradication of multidrug-resistant Acinetobacter baumannii in a 
female patient with total hip arthroplasty, with debridement and 
retention: a case report
Alison M Beieler*1, Robert W Belknap2, Michael R Dayton3, Connie S Price1 
and Steve J Morgan4
Address: 1Department of Medicine, Infectious Diseases, Denver Health Medical Center, 660 Bannock St, Denver, CO 80204, USA, 2Department of 
Medicine & Public Health, Infectious Diseases, Denver Health Medical Center, 605 Bannock St, Denver, CO 80204, USA, 3Department of 
Orthopedics, University of Colorado, 1635 N. Ursula St, Aurora, CO 80045, USA and 4Department of Orthopedics, Denver Health Medical Center, 
777 Bannock St, Denver, CO 80204, USA
Email: Alison M Beieler* - alison.beieler@dhha.org; Robert W Belknap - robert.belknap@dhha.org; 
Michael R Dayton - michael.dayton@uchsc.edu; Connie S Price - connie.price@dhha.org; Steve J Morgan - steven.morgan@dhha.org
* Corresponding author    
Abstract
Introduction:  Multidrug-resistant  Acinetobacter baumannii has become a significant cause of healthcare-
associated infections, but few reports have addressed Acinetobacter baumannii infections associated with
orthopedic devices. The current recommended treatment for complicated infections due to orthopedic devices,
including resistant gram-negative rods, consists of antimicrobial therapy with debridement and removal of
implants.
Case presentation: The patient, a 47-year-old woman, had previously had a prior total hip arthroplasty at 16
years of age for a complex femoral neck fracture, and multiple subsequent revisions. This time, she underwent a
fifth revision secondary to pain. Surgery was complicated by hypotension resulting in transfer to the intensive care
unit and prolonged respiratory failure. She received peri-operative cefazolin but postoperatively developed
surgical wound drainage requiring debridement of a hematoma. Cultures of this grew ampicillin-sensitive
Enterococcus and Acinetobacter baumannii (sensitive only to amikacin and imipenem). The patient was started on
imipenem. Removal of the total hip arthroplasty was not recommended because of the recent surgical
complications, and the patient was eventually discharged home. She was seen weekly for laboratory tests and
examinations and, after 4 months of therapy, the imipenem was discontinued. She did well clinically for 7 months
before recurrent pain led to removal of the total hip arthroplasty. Intra-operative cultures grew ampicillin-
sensitive Enterococcus and coagulase-negative Staphylococcus but no multidrug-resistant Acinetobacter baumannii.
The patient received ampicillin for 8 weeks and had not had recurrent infection at the time of writing, 37 months
after discontinuing imipenem.
Conclusion: We describe the successful treatment of an acute infection from multidrug-resistant Acinetobacter
baumannii with debridement and retention of the total hip arthroplasty, using monotherapy with imipenem. This
case challenges the general assumption that all orthopedic-device infections due to multidrug-resistant gram-
negative organisms will require hardware removal. Further studies are needed to determine if organisms such as
multidrug-resistant Acinetobacter baumannii are amenable to treatment with hardware retention.
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Introduction
Acinetobacter baumannii has become an important cause of
healthcare-associated infections worldwide [1]. The
organism has developed substantial antimicrobial resist-
ance, making treatment of infections attributed to A. bau-
mannii increasingly more difficult to manage. Multidrug-
resistant (MDR) A. baumannii is capable of causing a vari-
ety of infections, including urinary tract infections, pneu-
monia, bacteremia, as well as skin and soft tissue
infections [2]. It is found primarily in patients with pro-
longed stays in intensive care units and less commonly in
outpatients [3].
A. baumannii has been reported with increasing frequency
as a cause of device-associated infections, related to cath-
eters and mechanical ventilation [1,2]. Most recently,
MDR A. baumannii has been described as a cause of osteo-
myelitis in soldiers of the Iraq war [4] and in trauma
patients [5].
Despite its increasing frequency, there is little data in the
literature on the treatment of orthopedic-device infections
due to MDR A. baumannii, specifically on total joint
arthroplasties. The recently recommended approach for
treating infected arthroplasties is a two-step hardware
exchange with use of an antibiotic cement spacer (PROS-
TALAC) [6]. Here, however, we describe the eradication of
MDR A. baumannii total joint arthroplasty infection in a
patient using a debridement and retention approach with
imipenem-cilastatin (imipenem) monotherapy.
Case presentation
A 47-year-old woman was involved in a motor vehicle
accident at the age of 16 and suffered a right femoral neck
fracture. Open reduction internal fixation of the fracture
was not possible, and the primary therapy for the injury
was a total hip arthroplasty (THA). The patient required
four revisions of her primary total hip. She presented to
our center for consideration for a fifth revision surgery sec-
ondary to intractable pain. She was taken to the operating
room (OR) and received peri-operative cefazolin as per
protocol. Complications arose during the revision proce-
dure. A femoral shaft fracture occurred, and a deep pelvic
arterial injury resulted in intra-operative hemodynamic
instability, requiring suspension of the procedure and
arterial embolization. The patient was subsequently trans-
ferred to the intensive care unit and, on day 2 in hospital,
returned to the OR for completion of the original proce-
dure which was uneventful. Her postoperative course,
however, was complicated by prolonged respiratory fail-
ure necessitating a tracheostomy.
On day 12 in hospital, the patient developed increased
pain, redness and new drainage from her surgical wound.
She underwent surgical exploration, was found to have a
hematoma with evidence of defects in the deep fascia,
which required debridement down to the hip prosthesis.
The hematoma was evacuated, no antibiotic beads were
placed, and she was started on vancomycin. Quantitative
cultures were not performed; however, tissue cultures
grew ampicillin-sensitive Enterococcus species and A. bau-
mannii (sensitive only to amikacin and imipenem). The
patient was switched to imipenem 500 mg IV every 6
hours on day 15 in hospital. She was not considered to be
a candidate for removal of her prosthesis because of the
recent prior surgical complications.
On day 33 in hospital, the patient returned to the OR for
debridement because of continued fevers despite imi-
penem; cultures once again grew MDR A. baumannii, Ente-
rococcus  species and coagulase-negative Staphylococci
(CNS). The patient improved and was discharged home
on day 53 to complete her imipenem therapy at home.
The patient was seen weekly in our Orthopedic Infectious
Diseases Clinic for blood tests and clinical examination.
Due to persistently elevated inflammatory markers, eryth-
rocyte sedimentation rate (ESR) and C-reactive protein
(CRP), her antibiotic course was extended. Her ESR and
CRP improved but never normalized. The antibiotics were
stopped after completing a 4-month course of imipenem.
The patient was not placed on oral suppressive therapy
since no options existed for the MDR A. baumannii.
The patient remained symptom-free for 7 months before
noticing pain with walking and swelling at the right hip.
She denied having had any new injury or trauma. On
exam, she had redness, warmth, swelling and new drain-
age at the incision site on the right hip, presumed to rep-
resent recurrence of her MDR A. baumannii infection. At
this time, she underwent surgical debridement and
removal of the THA. Intra-operative cultures were
obtained but the prosthesis was not sonicated. The opera-
tive cultures grew Enterococcus species (sensitive to ampi-
cillin and penicillin), and two types of CNS (resistant to
penicillin), which were not thought to be pathogenic.
There was no MDR A. baumannii isolated. The patient
responded to an 8-week course of therapy directed only
toward the Enterococcus species with ampicillin. Twenty-
nine months after stopping antibiotics, she remains free
of infection at the time of writing.
Discussion
Acinetobacter is an aerobic gram-negative coccobacilli that
is catalase positive, oxidase negative, non-fermenting and
nonmotile [2]. Although it is usually a low-grade patho-
gen, it has several properties that can increase its viru-
lence. These include a capsule made of polysaccharide
(making the organism more hydrophilic), the capability
of adhesion to epithelial cells in the company of capsularJournal of Medical Case Reports 2009, 3:45 http://www.jmedicalcasereports.com/content/3/1/45
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polysaccharide, enzyme production which can injure
lipid components of tissue, and possibly a toxic-type func-
tion found in the cell wall lipopolysaccharide [2]. Acineto-
bacter is typically found in environmental areas such as
soil and aquatic areas [7]; thus, it can often be a contami-
nant associated with the environment. However, A. bau-
mannii  has recently been linked to hospital infections,
including surgical wound infections and device-related
infections [1,2].
In a healthcare setting, patients become colonized with
the organism on their skin, usually in moist places, the toe
webs, axillae and groin [2]. Acinetobacter can live in the
hospital setting for several days; it has been demonstrated
to survive on filter paper for up to 6 days, on Formica for
13 days and on cotton for 25 days [8]. Risk factors for
acquisition of MDR A. baumannii during outbreaks have
been described and include the use of broad-spectrum
antibiotics, longer hospitalization, advanced age,
mechanical ventilation, trauma intensive care unit and
the use of pulsatile lavage wound irrigation [2,9].
Before the year 1970, most Acinetobacter species were sen-
sitive to carbenicillin, ampicillin, gentamicin, or minocy-
cline [2]. Around 1975, Acinetobacter was documented as
developing resistance to many antibiotics including tetra-
cyclines, cephalosporins, cephamycins, aminopenicillins
and aminoglycosides [2]. MDR A. baumannii can be
defined as an organism resistant to over three classes of
antibiotics [4]. Some A. baumannii are sensitive to newer
cephalosporins (ceftazidime), quinolones, amikacin,
tobramycin and imipenem, but often with higher mini-
mum inhibitory concentrations than before [2].
Recently, increases in imipenem-resistant MDR A. bau-
mannii infections have lead to the use of colistin or poly-
myxin B for salvage therapy in severe cases [10]. Colistin
and polymyxin B have proven to be successful treatments
of MDR A. baumannii bacteremia, pneumonia, meningitis
and orthopedic-device infections in documented case
reports [10].
Recent cases of MDR A. baumannii infections in military
personnel have occurred in the form of bacteremia,
extremity war wounds and osteomyelitis [4]. In these
cases, osteomyelitis was documented via bone cultures
taken intra-operatively during open debridements or
internal/external fixation procedures [4]. Other patients
with symptoms of fever, increased white blood cell count,
open fractures with necrotic tissue and gross pus with
deep tissue cultures positive for MDR A. baumannii were
also classified as osteomyelitis [4]. In the military patients
treated for osteomyelitis, ampicillin/sulbactam, ceftazi-
dime and amikacin in combination with imipenem were
used successfully [4]. The duration of therapy in this small
study of 18 patients varied between 4 to 8 weeks of IV
treatment [4]. In a mean follow-up time of 9 months,
there were no recurrences of MDR A. baumannii infection
[4].
Previously published guidelines related to orthopedic
device infections suggest that prerequisites for debride-
ment and retention include short duration of symptoms,
satisfactory condition of soft tissue and the absence of dif-
ficult-to-treat resistant microorganisms [6], particularly
gram-negative organisms [11]. These guidelines, as they
relate to gram-negative pathogens such as A. baumannii as
well as MDR phenotypes, are based on little evidence and
mostly on speculation. This is due, in part, to the inability
to confirm microbiologic eradication of the offending
pathogen. In our patient's case, microbiologic eradication
was documented in a subsequent debridement several
months after antibiotics had been discontinued.
New information suggests that A. baumannii is capable of
forming biofilms on different surfaces, which may explain
in part why these infections are difficult to treat. A. bau-
mannii biofilms that adhere to various glass (hydrophilic)
and plastic (hydrophobic) surfaces were observed in
recent studies [12]. After allowing the organism to set for
approximately 10 to 15 minutes, the biofilm made by the
A. baumannii 19606 strain was shown to remain on both
Teflon strips and Petri dishes after washing with tap water
[12]. The A. baumannii biofilm demonstrated growth in
both static and dynamic environments and at varying
temperatures, verifying that an A. baumannii organism can
persevere and multiply in harsh conditions [12]. This
information suggests that device-related infections due to
A. baumannii require definitive antibiotic therapy and, if
treatment fails to be effective, possible device removal for
cure.
Conclusion
A. baumannii continues to emerge as an important cause
of trauma-associated infections and orthopedic device-
associated infections. Consequently, more evidence is
necessary to understand the importance of gram-negative
infections and MDR phenotypes, especially MDR A. bau-
mannii, and factors associated with failure when salvage is
attempted. It is interesting that the more sensitive gram-
positive organism (ampicillin-sensitive Enterococcus) per-
sisted in our patient despite active therapy against this
organism, again calling into question the assumption that
gram-negative organisms are inherently more difficult to
eradicate.
We described a case report of successful treatment of a
MDR A. baumannii infected THA with debridement and
retention, and 4 months of monotherapy using imi-
penem, with microbiologic eradication of MDR A. bau-Publish with BioMed Central    and   every 
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mannii, and no signs of recurrence with this organism at
37 months. Assumptions that orthopedic device infec-
tions due to gram-negative organisms and/or those with
multidrug-resistant phenotypes are not amenable to sal-
vage should be re-examined.
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